Education and Training
- M.B.B.Ch., University of Cambridge (UK), 1987
Tanimoto, A, Takeuchi, S, Arai, S, Fukuda, K, Yamada, T, Roca, X, Ong, ST, and Yano, S. "Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism-Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer." Clinical cancer research : an official journal of the American Association for Cancer Research 23, no. 12 (June 2017): 3139-3149.
Soh, SX, Siddiqui, FJ, Allen, JC, Kim, GW, Lee, JC, Yatabe, Y, Soda, M, Mano, H, Soo, RA, Chin, T-M, Ebi, H, Yano, S, Matsuo, K, Niu, X, Lu, S, Isobe, K, Lee, J-H, Yang, JC, Zhao, M, Zhou, C, Lee, J-K, Lee, S-H, Lee, JY, Ahn, M-J, Tan, TJ, Tan, DS, Tan, E-H, Ong, ST, and Lim, W-T. "A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer." Oncotarget 8, no. 25 (June 2017): 41474-41486.
Cherian, J, Nacro, K, Poh, ZY, Guo, S, Jeyaraj, DA, Wong, YX, Ho, M, Yang, HY, Joy, JK, Kwek, ZP, Liu, B, Wee, JLK, Ong, EHQ, Choong, ML, Poulsen, A, Lee, MA, Pendharkar, V, Ding, LJ, Manoharan, V, Chew, YS, Sangthongpitag, K, Lim, S, Ong, ST, Hill, J, and Keller, TH. "Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells." Journal of medicinal chemistry 59, no. 7 (April 2016): 3063-3078.
Ko, TK, Chin, HS, Chuah, CTH, Huang, JWJ, Ng, K-P, Khaw, SL, Huang, DCS, and Ong, ST. "The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia." Oncotarget 7, no. 3 (January 2016): 2721-2733.
Ong, ST, Pathiraja, T, Javed, A, Soh, XXS, Malik, S, Tan, JNJ, Ko, TK, Chuah, C, Takahashi, N, Bhatia, R, Ng, KP, Chng, WJ, Tennakoon, C, Hoi, Q, Guan, P, Teo, ASM, Lee, WH, Tan, P, Sung, WK, Ng, P, and Hillmer, A. "The Genomic and Epigenomic Landscapes of Blast Crisis Transformation in Chronic Myeloid Leukemia." December 3, 2015.
Ko, TK, Soh, XXS, Yu, W, Winter, PS, Pathiraja, T, Javed, A, Malik, S, Tan, JHJ, Chuah, C, Takahashi, N, Bhatia, R, Chng, WJ, Valent, P, Cerny-Reiterer, S, Ng, KP, Tennakoon, C, Hoi, Q, Guan, P, Teo, ASM, Lee, WH, Tan, P, Sung, WK, Ng, P, Hillmer, A, Wood, KC, Rozen, S, and Ong, ST. "Functional Analysis of the CML Blast Crisis Transcriptome and Epigenome Using Crispr-CAS9 and Pharmacologic Approaches." December 3, 2015.
Yano, S, Tanimoto, A, Arai, S, Fukuda, K, Ong, ST, and Takeuchi, S. "HDAC Inhibitors Overcome New Generation EGFR-TKI-Resistance Caused by Homozygous BIM Polymorphism in EGFR Mutant Lung Cancer." JOURNAL OF THORACIC ONCOLOGY 10, no. 9 (September 2015): S296-S297.
Than, H, Chuah, C, and Ong, ST. "Molecular mechanism of TKI resistance and potential approaches to overcome resistance." In Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia, 167-182. January 1, 2015.
Tsai, BP, Jimenez, J, Lim, S, Fitzgerald, KD, Zhang, M, Chuah, CTH, Axelrod, H, Wilson, L, Ong, ST, Semler, BL, and Waterman, ML. "A novel Bcr-Abl-mTOR-eIF4A axis regulates IRES-mediated translation of LEF-1." Open biology 4, no. 11 (November 2014): 140180-.
Ko, TK, Chuah, CTH, Huang, JWJ, Ng, K-P, and Ong, ST. "The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors." Oncotarget 5, no. 19 (October 2014): 9033-9038.